Medicamen Biotech Ltd-$
Medicamen Biotech Ltd-$ (MEDICAMEQ) last traded at ₹236, a market capitalisation of ₹320 crore, on a P/E of 29.6. Over the past 52 weeks the stock has ranged between ₹210 and ₹454. Medicamen Biotech Ltd-$ last reported results for the quarter ended Jun 2026, with sales of ₹47.9 crore and net profit of ₹1.85 crore. Medicamen Biotech Ltd-$’s annual general meeting is scheduled for 26 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Medicamen Biotech Ltd-$ share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Medicamen Biotech Ltd-$ quarterly results
In the quarter ended Jun 2026, sales were ₹47.9 cr, up 11.3% from ₹43.04 cr a year earlier. Net profit was ₹1.85 cr, up 15.6% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 44.74 | 45.14 | 29.61 | 43.04 | 47.17 | 46.91 | 60.65 | 47.9 |
| Expenses | 39.43 | 38.43 | 31.22 | 38.43 | 42.01 | 42.53 | 55.22 | 43.57 |
| Operating profit | 5.31 | 6.71 | -1.61 | 4.61 | 5.16 | 4.38 | 5.43 | 4.33 |
| OPM % | 11.87% | 14.86% | -5.44% | 10.71% | 10.94% | 9.34% | 8.95% | 9.04% |
| Other income | 0.29 | 0.14 | 5.23 | 0.47 | 0.37 | 0.53 | 1.74 | 0.86 |
| Interest | 1.04 | 0.76 | 0.65 | 1.15 | 0.99 | 0.97 | 0.38 | 0.83 |
| Depreciation | 2.61 | 2.21 | 0.48 | 1.8 | 1.86 | 1.83 | 1.73 | 1.79 |
| Profit before tax | 1.95 | 3.88 | 2.49 | 2.13 | 2.68 | 2.11 | 5.06 | 2.57 |
| Tax % | 53.85% | 24.74% | 25.30% | 24.88% | 21.27% | 22.27% | 12.06% | 28.40% |
| Net profit | 0.91 | 2.92 | 1.87 | 1.6 | 2.12 | 1.64 | 4.45 | 1.85 |
| EPS (₹) | 1.15 | 2.73 | 1.90 | 1.59 | 1.97 | 1.61 | 2.85 | 1.56 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Medicamen Biotech Ltd-$ annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 113 | 115 | 141 | 179 | 163 | 198 | 203 |
| Operating profit | 20 | 24 | 24 | 24 | 14 | 20 | 19 |
| OPM % | 17% | 21% | 17% | 13% | 9% | 10% | 10% |
| Net profit | 12 | 15 | 15 | 9 | 7 | 10 | 10 |
| EPS (₹) | 9.93 | 12.20 | 11.73 | 8.60 | 5.59 | 7.11 | 7.99 |
TTM is the trailing twelve months to the most recent quarter.
Medicamen Biotech Ltd-$ growth and returns
- 10 Years
- %
- 5 Years
- 12%
- 3 Years
- 12%
- TTM
- 25%
- 10 Years
- %
- 5 Years
- -4%
- 3 Years
- -13%
- TTM
- 14%
- 10 Years
- 3%
- 5 Years
- -17%
- 3 Years
- -31%
- 1 Year
- -33%
- 10 Years
- %
- 5 Years
- 6%
- 3 Years
- 4%
- Last Year
- 4%
Medicamen Biotech Ltd-$ shareholding pattern
Promoters held 40.46% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.07% and DIIs 0.40%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 42.99% | 42.99% | 43.16% | 40.46% | 40.46% | 40.46% | 40.46% | 40.46% |
| FIIs | 0.06% | 0.06% | 0.12% | 0.00% | 0.05% | 0.02% | 0.10% | 0.07% |
| DIIs | 1.17% | 0.87% | 0.69% | 0.64% | 0.59% | 0.44% | 0.00% | 0.40% |
| Government | 0.00% | 0.06% | 0.06% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% |
| Public | 55.79% | 56.04% | 55.99% | 58.83% | 58.84% | 59.02% | 59.39% | 59.01% |
| No. of shareholders | 10,792 | 10,576 | 10,435 | 10,808 | 11,177 | 10,967 | 10,806 | 11,047 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Medicamen Biotech Ltd-$’s AGM?
Medicamen Biotech Ltd-$’s annual general meeting is scheduled for 26 Sept 2026.
- AGM33rd Annual General Meeting and approval of final dividend
See the full results calendar for every Indian company reporting in the next 30 days.
Medicamen Biotech Ltd-$ corporate filings
- The Company has fixed Saturday, September 19, 2026 as the record date for determining the entitlement of members to receive the dividend, if declared at the ensuing AGM.Corp. Actionlow impact
Cruxal's analysis: Medicamen Biotech Limited has formally notified the stock exchanges that its Register of…
Read the full analysis - Announcement under Regulation 30 (LODR)- Newspaper Publication for the Unaudited Standalone and Consolidated Financial Results for the Qtr ended 30.06.2026Company Updatelow impact
Cruxal's analysis: Medicamen Biotech Limited has formally published its un-audited standalone and…
Read the full analysis - Board of Directors has been approved the closure of Register of Members and Share Transfer Books from September 19, 2026 to September 25, 2026 in connection with the proposed payment of ....Corp. Actionlow impact
Cruxal's analysis: Medicamen Biotech Ltd has scheduled the closure of its Register of Members and Share…
Read the full analysis - Financial Results for the quarter ended on June 30, 2026.Resultmedium impact
Cruxal's analysis: Medicamen Biotech Limited reported Q1 FY27 standalone revenue of INR 43.85 crore and a…
Read the full analysis - Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve the Unaudited Financial ....Board Meetinglow impact
Cruxal's analysis: Medicamen Biotech Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Medicamen Biotech Ltd-$
Cruxal reads every Medicamen Biotech Ltd-$ filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.